The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
A new phase II clinical trial is exploring the effects of two approved chemotherapy drugs administered after surgery to treat adult patients who have high-risk, well-differentiated pancreatic neuroendocrine tumors (pNETS).
Joe Castrovinci has been living with NETs (and living well!) since his diagnosis in 2012. Read about his NET journey and why he and his husband have included NETRF in their estate planning.
He was just FUN. Simply the nicest guy – always thinking of others. Perpetually positive – he only saw the glass as ‘half full.’ He
The European Neuroendocrine Tumor Society (ENETS) held its 19th Annual Conference earlier this month in Barcelona, Spain. The meeting brings together physicians and researchers from throughout the world to discuss the latest research on neuroendocrine cancer. More than 1500 participants attended in person or virtually. This year the meeting included the first World NET Forum, focusing on basic and translational science. NETRF was proud to sponsor the prizes for best abstracts.
The Neuroendocrine Tumor Research Foundation is thrilled to announce that it has achieved a 4-star rating from Charity Navigator for the seventh consecutive year for
The Neuroendocrine Tumor Research Foundation elected Todd Gillman as President of its Board of Directors at the January 2022 meeting. Gillman replaces longtime president Joseph Li, MD.
A new phase II clinical trial is evaluating the safety and effectiveness of 212Pb-DOTAMTATE in patients who have somatostatin receptor-expressing neuroendocrine tumors but who have not received peptide receptor radionuclide therapy, or PPRT.
The Neuroendocrine Tumor Research Foundation received a $5 million endowment gift from The Margie and Robert E. Petersen Foundation. This $5 million gift brings NETRF’s 2021 fundraising total to $7.26 million to fund NET research around the globe.
NETRF elects Suzanne Ludlow to its Board of Directors. Suzanne first became involved with NETRF after her late husband Vince’s journey with neuroendocrine cancer. Read more.
NETRF’s 2021 accomplishments were possible because of you! With the support of our donors, NET researchers, and the patient community, we had a successful year that surpassed our expectations. Thank you for your wonderful generosity.
